As the EU deadline draws near for drug sponsors to finish reviewing their medicines for the presence of cancer-causing N-nitrosamines impurities, the European medicines regulatory network has agreed on practical steps it intends to take if impurities are detected in marketed drugs.
The arrangements are listed in a plan published on 22 February. It outlines specific measures that EU regulators intend to follow if N-nitrosamine impurities are found in a marketed medicine...